期刊
EMERGING MICROBES & INFECTIONS
卷 10, 期 1, 页码 37-50出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2020.1862631
关键词
Hepatitis B virus; Hepatitis B e antigen; monoclonal antibody; cccDNA surrogate; immunoassay
资金
- National Natural Science Foundation of China [U1905205, 81902057, 81702006]
- National Science and Technology Major Project of Infectious Diseases [2017ZX10202203-009003]
In this study, a novel method for detecting HBeAg was developed with high sensitivity and specificity, able to detect HBeAg from various HBV genotypes without cross-reactivity with HBcAg. This new method could be useful in drug screening and clinical HBeAg detection.
Hepatitis B e antigen (HBeAg) is a widely used marker both for chronic hepatitis B (CHB) clinical management and HBV-related basic research. However, due to its high amino acid sequence homology to hepatitis B core antigen (HBcAg), most of available anti-HBe antibodies are cross-reactive with HBcAg resulting in high interference against accurate measurement of the status and level of HBeAg. In the study, we generated several monoclonal antibodies (mAbs) targeting various epitopes on HBeAg and HBcAg. Among these mAbs, a novel mAb 16D9, which recognizes the SKLCLG (aa -10 to -5) motif on the N-terminal residues of HBeAg that is absent on HBcAg, exhibited excellent detection sensitivity and specificity in pairing with another 14A7 mAb targeting the HBeAg C-terminus (STLPETTVVRRRGR, aa141 to 154). Based on these two mAbs, we developed a novel chemiluminescent HBeAg immunoassay (NTR-HBeAg) which could detect HBeAg derived from various HBV genotypes. In contrast to widely used commercial assays, the NTR-HBeAg completely eliminated the cross-reactivity with secreted HBcAg from precore mutant (G1896A) virus in either cell culture or patient sera. The improved specificity of the NTR-HBeAg assay enables its applicability in cccDNA-targeting drug screening in cell culture systems and also provides an accurate tool for clinical HBeAg detection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据